• XPOVIO^® is the first and only approved XPO1 inhibitor in Thailand.
• XPOVIO^® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug application (NDA) for XPOVIO^® in Indonesia with approval expected in the second half of 2024.
• XPOVIO^® has been approved for health insurance coverage in the mainland of China, Australia, Singapore and South Korea.

SHANGHAI and HONG KONG, Sept. 23, 2024 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced that the Thailand Food and Drug Administration has approved a New Drug Application (NDA) for XPOVIO^® (selinexor) for two indications: (1) In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma(MM) who have received at least one prior therapy; and (2) in combination with dexamethasone for the treatment of adult patients with MM who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.